Article
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2016
Tissot Claire, Couraud Sébastien, Tanguy Ronan, Bringuier Pierre-Paul, Girard Nicolas, Souquet Pierre-Jean
Abstract excerpt
INTRODUCTION: BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations are identified in approximately 2% of non-small cell lung cancer (NSCLC). Because of the rarity of those mutations, associated clinical features and prognostic significance have not been thoroughly described so far. METH...
Topics
- Aged
- Carcinoma, Non-Small-Cell Lung
- Case-Control Studies
- Class I Phosphatidylinositol 3-Kinases
- ErbB Receptors
- Female
- Genotype
- Humans
- Imidazoles
- Lung Neoplasms
- Male
- Middle Aged
- Mutation
- Oximes
- Phosphatidylinositol 3-Kinases
- Prognosis
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf